

Anti-CLEC4C Antibody (BIIB059)

Introduction

Litifilimab is a humanized IgG1-κ antibody targeting C-type lectin domain family 4 member C (CLEC4C). Litifilimab is used in the research of cutaneous lupus erythematosus (CLE).

Product parameters

Alternative Names	Litifilimab
Target Accession	Q8WTT0
Target	CLEC4C
CAS number	2407378-48-5
Molecular Weight	146.6 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized Ma CLEC4C His at 2 ug/mL can bind Anti-CLEC4C Antibody (BIIB059), EC50=0.04315 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

